|
|
Blood, 15 November 2004, Vol. 104, No. 10, pp. 3052-3057.
Prepublished online as a Blood First Edition Paper on July 20, 2004; DOI 10.1182/blood-2004-02-0408.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
Antonio Palumbo,
Sara Bringhen,
Maria Teresa Petrucci,
Pellegrino Musto,
Fausto Rossini,
Martina Nunzi,
Vito Michele Lauta,
Cesare Bergonzi,
Anna Barbui,
Tommaso Caravita,
Antonio Capaldi,
Patrizia Pregno,
Tommasina Guglielmelli,
Mariella Grasso,
Vincenzo Callea,
Alessandra Bertola,
Federica Cavallo,
Patrizia Falco,
Cecilia Rus,
Massimo Massaia,
Franco Mandelli,
Angelo Michele Carella,
Enrico Pogliani,
Anna Marina Liberati,
Franco Dammacco,
Giovannino Ciccone, and
Mario Boccadoro
From the Divisione di Ematologia dell' Università di Torino and Struttura Complessa (SC) Ematologia Ospedaliera and Epidemiologia dei Tumori, Azienda Ospedaliera S. Giovanni Battista, and Divisione di Ematologia e Malattie Trombotiche, Ospedale Evangelico Valdese, Torino, Italy; Dipartimento di Biotecnologie ed Ematologia, Università La Sapienza and Cattedra e Divisione di Ematologia, Università Tor Vergata, Ospedale S. Eugenio, Roma, Italy; Unitá Operativa (UO) di Ematologia e Trapianto di Cellule Staminali, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy; Ematologia, H. S. Gerardo, Monza, Italy; Clinica medica I, Policlinico Monteluce, Perugia, Italy; Sezione di Medicina Interna e Oncologia clinica, Policlinico, Bari, Italy; Sezione di Ematologia, Azienda Istituti Ospedalieri, Cremona, Italy; Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy; Divisione di Oncologia ed Ematologia, IRCCS, Candiolo, Italy; Medicina Interna II, Azienda Ospedaliera San Luigi, Orbassano, Italy; Divisione di Ematologia, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy; Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy.
High-dose therapy is an effective standard treatment for multiple myeloma patients. Evidence that intermediate-dose therapy improves survival is limited. At diagnosis, about 70% of patients are older than 65. Intermediate-dose regimen is very well tolerated in older patients. In a multicenter study, 194 patients were randomized to receive at diagnosis either conventional chemotherapy (6 courses of oral melphalan and prednisone [MP]) or intermediate-dose therapy (2 courses of melphalan at 100 mg/m2 [MEL100]) with stem cell support. Response rate was higher after MEL100. Near-complete remission (nCR) was 6% after MP and 25% after MEL100 (P = .0002). At 3 years, MEL100 increased event-free survival (EFS) from 16% to 37% and overall survival (OS) from 62% to 77% (P < .001). Similar results were observed in patients aged 65 to 70: nCR was 8% after MP and 25% after MEL100 (P = .05); at 3 years, MEL100 improved EFS from 18% to 31% (P = .01) and OS from 58% to 73% (P = .01). Patients aged 65 to 70 had a median OS of 37.2 months (MP) versus 58 months (MEL100). Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Too old for transplantation: think again
- Morie A. Gertz
Blood 2004 104: 3000-3001.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. Mehta
One or two autografts for myeloma?
Blood,
April 1, 2008;
111(7):
3899 - 3900.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Fermand
Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation
ASCO Educational Book,
January 1, 2008;
2008(1):
375 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Di Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omede, M. T. Ambrosini, et al.
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network
J. Clin. Oncol.,
October 1, 2007;
25(28):
4459 - 4465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omede, I. Baldi, et al.
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
N. Engl. J. Med.,
March 15, 2007;
356(11):
1110 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Niscola, C. Romani, L. Cupelli, L. Scaramucci, A. Tendas, T. Dentamaro, S. Amadori, and P. de Fabritiis
Mucositis in patients with hematologic malignancies: an overview
Haematologica,
February 1, 2007;
92(2):
222 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau
Stem Cell Transplantation in Multiple Myeloma
Hematology,
January 1, 2007;
2007(1):
311 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E.H.M. Van Hoef
Myeloma Treatment Plan: Up-Front Dose-Dense Chemotherapy, Two Semi-High-Dose Autologous Transplants and a Non-Myeloablative Reduced Intensity Allogeneic Transplant.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
5355 - 5355.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Attal, J.-L. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, L. Benboubker, I. Y. Agha, J.-H. Bourhis, L. Garderet, B. Pegourie, et al.
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Blood,
November 15, 2006;
108(10):
3289 - 3294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Offidani, L. Corvatta, M.-N. Piersantelli, G. Visani, F. Alesiani, M. Brunori, P. Galieni, M. Catarini, M. Burattini, R. Centurioni, et al.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Blood,
October 1, 2006;
108(7):
2159 - 2164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood,
October 1, 2006;
108(7):
2165 - 2172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, et al.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
Blood,
May 1, 2006;
107(9):
3474 - 3480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Berenson, H. H. Yang, K. Sadler, S. G. Jarutirasarn, R. A. Vescio, R. Mapes, M. Purner, S.-p. Lee, J. Wilson, B. Morrison, et al.
Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
J. Clin. Oncol.,
February 20, 2006;
24(6):
937 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology,
January 1, 2006;
2006(1):
338 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Fermand, S. Katsahian, M. Divine, V. Leblond, F. Dreyfus, M. Macro, B. Arnulf, B. Royer, X. Mariette, E. Pertuiset, et al.
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
J. Clin. Oncol.,
December 20, 2005;
23(36):
9227 - 9233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kober, N. Skoetz, S. Trelle, J. Bohlius, and A. Engert
Third Biannual Report of the Cochrane Haematological Malignancies Group
J Natl Cancer Inst,
August 17, 2005;
97(16):
E2 - E.
[Full Text]
|
|
|
|
|
|
|
D. E. Reece
An Update of the Management of Multiple Myeloma: The Changing Landscape
Hematology,
January 1, 2005;
2005(1):
353 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
